Navigation Links
In the Psoriasis Drug Market, Continued Uptake of Janssen's Stelara and the Launch of Emerging Systemic Therapies Will Drive Sales Growth to Nearly $9.2 Billion in 2022
Date:10/21/2013

his is supported by years of postmarketing safety data and will drive sales in the second half of the 2012-2022 forecast period. Beginning in 2014, the TNF-alpha inhibitors and Stelara will experience competition from emerging biologics and oral agents with novel mechanisms of action. Although concerns about their undefined safety profiles will restrict uptake initially, the emerging IL-17 inhibitors, Xeljanz, and Merck's IL-23 inhibitor MK-3222, will increase competition within the TNF-alpha-refractory space. Celgene's oral phosphodiesterase-4 inhibitor apremilast—which is also poised to enter the market in 2014—may see use in earlier lines of therapy than the emerging biologics and Xeljanz.

"Of the emerging systemic agents, the three IL-17 inhibitors—secukinumab, ixekizumab, and brodalumab—as well as MK-3222, have shown the most impressive efficacy. The efficacy of ixekizumab and brodalumab in Phase II clinical trials appears comparable to the most effective biologic for psoriasis, Janssen/Merck/Mitsubishi Tanabe's Remicade, and Phase III clinical trial data for secukinumab suggests impressive efficacy comparable to the two other agents in this drug class," said Decision Resources Business Insights Analyst Kathryn Beane. "Nevertheless, reservations about these agents' novel mechanisms of action and relatively limited safety profiles will mean that physicians will reserve these drugs initially for patients who have failed TNF-alpha inhibitors and Stelara."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfoli
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Stiefel, a GSK company, enters agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis
2. Virobay and LEO Pharma Initiate a Phase 1 Trial of VBY-891, a Compound Intended for Oral Treatment of Psoriasis
3. For Moderate to Severe Psoriasis, Thought Leaders Opinions and Clinical Data Indicate That Emerging Biologics That Target IL-17 Have the Potential to Offer Improvements in Efficacy and Safety Over Current Therapies
4. AbGenomics International has raised $9.6 million for advancing its psoriasis phase-II trials in US
5. Moleculin Reports Positive Data From Controlled Study of Novel Topical Psoriasis Treatment
6. Flu season threat greater for people with psoriasis and psoriatic arthritis who are taking immunosuppressive drugs
7. Heightened Awareness, Coupled with Expanding Patient Pool, Stimulates Sleep Apnea Diagnostics and Sleep Services Market, Says Frost & Sullivan
8. MicroRNA Research to Trigger Tremendous Growth in Related Tools Market, Says Frost & Sullivan
9. Varying Technology and Application Trends Pep up the Mature Research Antibodies Market, Finds Frost & Sullivan
10. Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition
11. For Drug Manufacturers Bringing a New Product to Market, Gaining the Support of Influential Doctors Is a Mission-Critical Priority
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014  Hologic, Inc. (NASDAQ: ... , Hologic,s President and Chief Executive Officer, will preside ... October 1, the first day of Breast Cancer Awareness ... Company,s campaign focused on the important benefits of Hologic,s ... the FDA as clinically superior to traditional mammography. ...
(Date:9/30/2014)... Md. , Sept. 30, 2014  Tasly ... way to modernize medicine, announced today the launch ... of nutraceuticals developed to address men and women ... healthy and vibrant into old age while helping ... includes three condition-specific, whole-food and herb-based formulas, namely, ...
(Date:9/30/2014)... Sept. 30, 2014 STUDY OBJECTIVES ... is to provide an overview of the current ... protein drugs/therapeutics. The key objective is to present ... drugs as an important tool in the treatment ... and future strategies within the protein therapeutics market, ...
Breaking Medicine Technology:Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 3Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 2Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 3Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 4
... , PITTSBURGH , June 17 Mylan ... Mylan Pharmaceuticals Inc. received final approval from the U.S. Food ... (ANDA) for Hydroxyzine Hydrochloride Tablets 10 mg, 25 mg and ... therefore, therapeutically equivalent to Pliva,s Hydroxyzine Hydrochloride Tablets, a treatment ...
... Copan unveiled new groundbreaking features of its Walk-Away Specimen ... American Society for Microbiology (ASM) in San Diego, California ... to the market in 2008 with the launch of the ... all microbiology samples. While attending the 110th ASM meeting, Copan ...
Cached Medicine Technology:Mylan Receives Approval for Hydroxyzine Hydrochloride Tablets 2Copan Redefines Automated Specimen Processing with Groundbreaking New Features 2Copan Redefines Automated Specimen Processing with Groundbreaking New Features 3
(Date:10/2/2014)... By Dennis Thompson ... -- Forty-two states and the District of Columbia now have ... severe respiratory illness that has been infecting children since ... infected with the virus have died in recent weeks, but ... virus played in those deaths, officials said. Health officials ...
(Date:10/1/2014)... Journal of the American Medical Association shows ... or severe chronic knee pain, acupuncture did not provide ... randomly assigned 282 patients (50 years or older) with ... pretend laser treatment. , Treatments were delivered for ... and sham (inactive) laser acupuncture. , Researcher Professor Kim ...
(Date:10/1/2014)... New research suggests the adage that encourages people to ... target when it comes to exercise. When walking, staying ... distance to it appear shorter and help people walk ... compares this technique to walking while looking around the ... quality of exercise. , "People are less interested in ...
(Date:10/1/2014)... 2014 Lifeinsurance-policy.com has released a ... life insurance prices for smokers. , Smoking will always ... Comparing quotes is the best method to find affordable ... customers who need coverage. , Whole life insurance ... the policy. Since the coverage is permanent, the initial ...
(Date:10/1/2014)... LOUIS, MO (PRWEB) October 01, 2014 Join ... for Castlewood Eating Disorder Treatment Center’s first ever charity golf ... grants for people with eating disorders who cannot afford treatment. ... Run Golf Club in Eureka, Mo. , The day-long ... at noon. A reception and award dinner will begin at ...
Breaking Medicine News(10 mins):Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3
... -- About one-fourth of all black men and women carry ... artery disease, new research reveals. The mutation is found ... higher risk for heart disease among other races, the ... and women who carry this single variation, the risk for ...
... College of Medicine and Dentistry (PCMD), University of Exeter, is ... form a 6m research and analysis network, funded by the ... the possible role of virus infection in the cause of ... lead to the development of a vaccine to prevent diabetes ...
... Injury Research and Policy of The Research Institute at ... adolescents 6 to 18 years old and found that ... departments from 1994 through 2007, for an average of ... study period, the annual number of running-related injuries increased ...
... , THURSDAY, Jan. 27 (HealthDay News) -- Work-related ... has found. Israeli researchers gave hearing tests to 298 ... harmful noise and found that 99 of the workers had ... hearing problems tended to be older and to have been ...
... Illinois study provides convincing evidence that the way you ... that teaming broccoli with broccoli sprouts may make the ... prepared correctly, is an extremely potent cancer-fighting agentthree to ... effect. To get broccoli,s benefits, though, the enzyme myrosinase ...
... of psychological resources, such as commitment and a sense of ... lead to loss of resources and other negative affects. This ... of Haifa. "Mass media plays a central role in reporting ... watching this type of coverage on television has negative effects, ...
Cached Medicine News:Health News:Gene Mutation May Protect Blacks From Heart Disease 2Health News:6 million euros for European Diabetes Research Network 2Health News:Sprouts? Supplements? Team them up to boost broccoli's cancer-fighting power 2Health News:Watching TV coverage of terror makes viewers feel threatened 2
Suture Cutters, Straight...
Suture scissor...
Threaded cannula for use with Suretac® II, sterile packs, box of 10....
The Small Oval Cannula System is designed to be the smallest oval cannula system currently available, and is utilized with the Caspari Suture Punch System. Disposable seals are available with this sy...
Medicine Products: